Source linked

ANDI transforme Amblyopia Care en un moteur de décision basé sur le Web

Trois enfants sur 100 aux États-Unis souffrent d'amblyopie, mais les spécialistes de l'œil pédiatrique sont inégalement répartis. le nouvel outil web du NIH, ANDI, fournit des plans de traitement fondés sur des preuves à tout clinicien, élargissant l'accès aux soins.

andipediatric eye disease investigator groupnihdeveloper toolspediatricsvision health

Three in every 100 U.S. children suffer amblyopia, yet pediatric eye specialists are unevenly distributed.

Amblyopia: The Silent Vision Threat

Amblyopia, the leading cause of preventable monocular vision loss, develops when the brain fails to fuse images from both eyes during early childhood. Misalignment, unequal refractive error, or visual blockage can trigger the condition. If untreated, the resulting vision deficit becomes permanent, and no amount of glasses or contacts can restore it in adulthood. Long‑term consequences ripple into school performance, employment prospects, and overall quality of life.

ANDI: From Evidence to Practice

The Amblyopia Navigator Decision‑Support Instrument (ANDI) translates 147 peer‑reviewed studies into a step‑by‑step treatment roadmap. Clinicians enter a handful of clinical findings—such as visual acuity, refractive error, and alignment status—and the tool outputs a personalized glasses prescription, monitoring schedule, and, if glasses alone prove insufficient, a sequence of evidence‑based interventions: patching, atropine, or emerging digital therapies. For practitioners without pediatric specialization, ANDI also flags when to intensify treatment or refer to a specialist. The web interface, hosted at https://public.jaeb.org/pedig, offers downloadable reference sheets for offline use.

Impact on Access and Care

Workforce studies reveal stark geographic clustering of pediatric optometrists and ophthalmologists, leaving many states devoid of specialists. By equipping general eye doctors with a concise, data‑driven protocol, ANDI promises to shrink these gaps. Early detection remains the key, and the tool’s ability to guide treatment across all ages means that children who otherwise would wait months for a specialist can begin therapy sooner. The result: higher treatment success rates, reduced long‑term disability, and a more equitable distribution of pediatric vision care.

As ANDI rolls out nationwide, it may set a new standard for translating research into bedside practice for any chronic condition.


Source: NIH-supported project expands access to care for children with amblyopia
Domain: nih.gov

Read original source ->

External source stays available while the OJO article and comment thread stay local.

Comments load interactively on the live page.